Table 3.
Comparison of the Molecular Epidemiology Resource (MER; 2002–12, restricted to age 20–79 years) with SEER data
| MER | MER-Minnesota and Iowa | SEER-Iowa | SEER-All | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % dist | 3-year observed survival (95% CI) | N | % dist | 3-year observed survival (95% CI) | N | % dist | 3-year observed survival | N | % dist | 3-year observed survival | |
| All | 5033 | 100.0% | 85% (84–86) | 3299 | 100.0% | 84% (83–85) | 9,348 | 100.0% | 77.2% | 206,373 | 100.0% | 74.9% |
| Sex | ||||||||||||
| Male | 2998 | 59.6% | 84% (83–85) | 1968 | 59.7% | 83% (81–85) | 5321 | 56.9% | 76.0% | 118094 | 57.2% | 73.0% |
| Female | 2035 | 40.4% | 86% (84–88) | 1331 | 40.3% | 86% (84–88) | 4027 | 43.1% | 78.8% | 88279 | 42.8% | 77.5% |
| Age group | ||||||||||||
| < 40 | 564 | 11.2% | 90% (88–93) | 397 | 12.0% | 91% (88–94) | 859 | 9.2% | 91.1% | 24194 | 11.7% | 84.4% |
| 40–49 | 694 | 13.8% | 91% (89–93) | 458 | 13.9% | 90% (87–93) | 883 | 9.4% | 86.6% | 24483 | 11.9% | 81.0% |
| 50–59 | 1223 | 24.3% | 88% (86–90) | 781 | 23.7% | 86% (83–88) | 1802 | 19.3% | 82.3% | 42633 | 20.7% | 80.3% |
| 60–69 | 1499 | 29.8% | 84% (82–86) | 962 | 29.2% | 81% (81–86) | 2587 | 27.7% | 78.1% | 55759 | 27.0% | 75.7% |
| 70–79 | 1053 | 20.9% | 75% (73–78) | 701 | 21.2% | 76% (73–80) | 3217 | 34.4% | 67.1% | 59304 | 28.7% | 63.9% |
| NHL subtype | ||||||||||||
| DLBCL | 902 | 17.9% | 77% (74–80) | 623 | 18.9% | 76% (73–80) | 2258 | 24.2% | 66.9% | 49280 | 23.9% | 63.9% |
| FL | 849 | 16.9% | 93% (92–95) | 588 | 17.8% | 93% (91–95) | 1444 | 15.4% | 87.2% | 28980 | 14.0% | 86.5% |
| CLL/SLL | 1133 | 22.5% | 92% (91–94) | 692 | 21.0% | 93% (91–95) | 2253 | 24.1% | 85.0% | 40254 | 19.5% | 84.0% |
| MCL | 227 | 4.5% | 72% (67–79) | 144 | 4.4% | 73% (66–81) | 282 | 3.0% | 64.9% | 5617 | 2.7% | 60.1% |
| MZL | 390 | 7.7% | 93% (91–96) | 228 | 6.9% | 91% (87–94) | 655 | 7.0% | 86.7% | 14240 | 6.9% | 87.7% |
| HL | 462 | 9.2% | 91% (88–94) | 340 | 10.3% | 91% (88–95) | 865 | 9.3% | 88.2% | 20899 | 10.1% | 85.6% |
| TCL | 309 | 6.1% | 63% (58–69) | 195 | 5.9% | 65% (58–72) | 568 | 6.1% | 64.8% | 15150 | 7.3% | 64.1% |
| Race | ||||||||||||
| White | 4821 | 97.7% | 85% (84–86) | 3231 | 97.9% | 84% (83–86) | 9069 | 97.0% | 77.1% | 173441 | 84.0% | 75.6% |
| Black | 112 | 2.2% | 85% (80–92) | 68 | 2.1% | 79% (69–89) | 122 | 1.3% | 75.0% | 17729 | 8.6% | 67.3% |
DLBCL, diffuse large B-cell lymphoma; dist, distribution; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukaemia/small lymphocytic lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; HL, Hodgkin lymphoma; TCL, T-cell lymphoma; NHL, non-Hodgkin lymphoma.